GLP-1 Peptides: The Science of the Class

This guide belongs to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management protocols, and the genetics of metabolism into plain language you can actually use.

The phrase "GLP-1 peptides" points at a real chemistry question. Most medications in this class are peptides, engineered versions of a natural hormone, and understanding that origin explains why they are dosed the way they are and why newer non-peptide options are notable. This page starts with the molecule itself and builds outward to the class and its genetics. Knowing whether a medication is a peptide, and what that implies for how it is dosed and delivered, turns an abstract label into practical understanding.

Is GLP-1 a peptide?

Yes. Glucagon-like peptide-1 is a small peptide hormone released by enteroendocrine L-cells in the small intestine after meals. It drives glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon from alpha cells, slows gastric emptying, and cues satiety in the hypothalamus. Its natural half-life is only minutes, because the enzyme DPP-4 degrades it almost as fast as the gut releases it.

How the peptides are engineered

GLP-1 receptor agonists are peptides modified to resist DPP-4 degradation, which stretches their activity from minutes to hours or days. They bind the same GLP-1 receptor as the native hormone and reproduce its downstream effects at a pharmacological level: insulin secretion, glucagon suppression, delayed gastric emptying, and reduced appetite through central satiety signaling. Dual GIP/GLP-1 agonists such as tirzepatide add engagement at a second incretin receptor.

The compounds in the class

FDA-approved GLP-1 receptor agonists as of April 2026 include exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and semaglutide (Ozempic, Wegovy, Rybelsus); lixisenatide was marketed historically but discontinued in the U.S. The dual GIP/GLP-1 agonist is tirzepatide (Mounjaro, Zepbound). See GLP-1 Drugs for the fuller roster.

Where non-peptide options are heading

Not every future entry is a peptide. The investigational triple agonist retatrutide (GLP-1, GIP, and glucagon) has Phase 3 data but is not FDA-approved and is not sold by PlexusDx. Emerging oral non-peptide GLP-1 receptor agonists such as orforglipron are in late-stage development, hinting that the class may broaden beyond its peptide roots. For the hormone background, see GLP-1 Hormone.

Shared safety across the peptides

All FDA-approved GLP-1 and GIP/GLP-1 agonists carry a boxed warning for thyroid C-cell tumor risk seen in rodent studies, and share contraindications for medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2. Gastrointestinal effects are the most common report and peak during dose escalation; rarer serious events include pancreatitis, gallbladder disease, and dehydration-related acute kidney injury.

Why the peptide origin shapes how they are used

The peptide nature of these medications is not just trivia; it explains practical realities. Because peptides are broken down in the gut and by enzymes like DPP-4, most were designed for subcutaneous injection and engineered for durability, which is why weekly and daily formats dominate the class. It is also why an oral peptide option is comparatively rare, and why the emergence of non-peptide small molecules in late-stage development is genuinely notable: a small molecule can be built with different absorption properties. Understanding that a medication is a modified natural peptide, rather than a wholly synthetic drug, gives useful intuition for why the class behaves the way it does, from dosing cadence to the biological effects it reproduces from the native hormone.

The genetic layer sitting underneath every GLP-1 decision

Variants in FTO, GLP1R, MC4R, and TCF7L2 shape baseline GLP-1, appetite regulation, and energy balance. None of these variants forecast how a particular medication will behave in your body, and the Precision Peptide Genetic Test is not a pharmacogenomic tool. What it does is map trait-level tendencies across your metabolism: this single 503A-appropriate readout covers 14 pathways, 49 peptides, 150+ genetic insights, giving you and your clinician a shared picture of the terrain before any protocol begins.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols.

Frequently Asked Questions

Are all GLP-1 medications peptides?

Most approved ones are peptides engineered from native GLP-1 to resist rapid breakdown. That is changing at the frontier: oral non-peptide small molecules such as orforglipron are in late-stage development. So the class is peptide-dominated today but may not stay exclusively peptide-based in the years ahead.

Why does native GLP-1 last only minutes?

Because the enzyme DPP-4 degrades it almost immediately in circulation. That short half-life is exactly the problem drug developers solved: receptor agonists are modified so DPP-4 cannot break them down quickly, extending activity from minutes to hours or days and making practical dosing schedules possible.

What is the difference between a peptide agonist and a dual agonist?

A single-receptor peptide agonist engages only the GLP-1 receptor. A dual agonist such as tirzepatide engages both the GLP-1 and GIP receptors, adding a second incretin mechanism. Both are peptides, but the dual design broadens the receptor targets the molecule activates.

Does genetic testing predict how I respond to these peptides?

No. The Precision Peptide Genetic Test does not predict response to any compound in the class. It analyzes pathway-level variants in genes like FTO, and MC4R that shape baseline biology, giving context for a provider conversation rather than a prediction about any specific peptide.